Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor

British Journal of Cancer

Volumn 78, Issue 1, 1998, Pages 88-95

  Levenson, A S ^b   Kwaan, H C ^b   Svoboda, K M ^b   Weiss, I M ^b   Sakurai, S ^b   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

Breast cancer; ER; ICI 182,780; Oestradiol; PAI 1; tPA; uPAa; uPAR

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; MUTANT PROTEIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 0031835192     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.447     Document Type: Article

References (58)

1. Bastholm L, Nielsen MH, De May J, Danø K, Brünner N, Høyer-Hansen G, Rønne E, and Elling F (1994) Confocal fluorescence microscopy of urokinase plasminogen activator receptor and cathepsin D in human MDA-MB-231 breast cancer cells migrating in reconstituted basement membrane. Biotech Histochem 69:61-67
2. Butler WB and Fontana JA (1992) Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7. Cancer Res 52: 6164-6167
3. Butler WB, Kirkland WL and Jorgensen TL (1979) Induction of plasminogen activator by estrogen in human breast cancer cell line (MCF-7). Biochem Biophys Res Comm 90: 1328-1334
4. Butler WB, Kirkland WL, Gagala TL, Goran N, Kelsey WH and Berlinski PJ (1993) Steroid stimulation of plasminogen activator production in human cancer cell line (MCF-7). Cancer Res 43: 1637-1641
5. Catherino WH, Wolf DM and Jordan VC (1995) A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analogue. Mol Endocrinol 9: 1053-1063
6. Danø K, Andreasen PA, Gröndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139- 266
7. Davis MD, Butler WB and Brooks SC (1995) Induction of tissue plasminogen activator mRNA and activity by structurally altered estrogens. J Steroid Biochem Mol Biol 52: 421-430
8. DePetro G, Vartio T, Salonsen EM, Vaheri A and Barlati S (1984) Tissue-type plasminogen activator, but not urokinase, exerts transformation-enhancing activity. Int J Cancer 33: 563-567
9. DePetro G, Copeta A and Barlati S (1994) Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts. Exp Cell Res 213: 286-294
10. Deutsch DG and Mertz ET (1970) Plasminogen purification from human plasma by affinity chromatography. Science 170: 1095-1096
11. Dickerman HW, Martinez HL, Seeger JI and Kumar SA (1989) Estrogen regulation of human breast cancer cell line MCF-7 tissue plasminogen activator. Endocrinology 125: 492-500
12. Duffy MJ, O'Grady P, Simon J, Rose M and Lijnen HR (1986) Tissue-type plasminogen aclivator in breast cancer: relationship with estradiol and progesterone receptors. J Natl Cancer Inst 77: 621-623
13. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ (1988) Urokinase plasminogen activator, a marker for aggressive breast carcinomas: Preliminary report. Cancer 62: 531-533
14. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreason P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
15. Duggan C, Maquire T, McDermott E, O'Higgins N, Fennelly JJ and Duffy MJ (1995) Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600
16. Ellis V, Behrendt N and Danø K (1991) Plasminogen activation by receptor-bound urokinase. J Biol Chem 266: 12752-12758
17. Fernö M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D (1996) Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analyzed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801
18. Foekens JA, Schmitt M, van Puten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM (1992) Prognostic value of urokinase-type plasminogen activator on 671 primary breast cancer patients. Cancer Res 52: 6101-6105
19. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Jänicke K and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658
20. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H and Klijn JGM (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1-predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756
21. Fujimoto J, Hori M, Ichigo S and Tamaya T (1996) Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa. J Steroid Biochem Mol Biol 59: 1-8
22. Gohring UJ, Scharl A, Thelen U, Ahr A and Titius BR (1995) Prognostic significance of immunohistochemical detection of urokinase plasminogen activator in primary breast carcinomas. Pathologe 16: 398-403
23. Granneli-Piperno A and Reich E (1978) A study of protease and protease-inhibitor complexes in biological fluids. J Exp Med 148: 223-234
24. Gröndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Dano K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
25. Gröndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Ronne E, Danø K, Klijn JGM, Brünner N and Foekens JA (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087
26. Gröndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK and Brünner N (1997) Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153-163
27. He CJ, Rebibou JM, Peraldi MN, Meulders Q and Rondeau E (1991) Growth factor-like effect of urokinase type plasminogen activator in human renal cells. Biochem Biophys Res Comm 176: 1408-1416
28. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Rømer J, Ellis V and Brünner N (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14: 297-307
29. Huff KK and Lippman ME (1984) Hormonal control of plasminogen activator secretion in ZR-75-1 breast cancer cells in culture. Endocrinology 114: 1702-1710
30. Jänicke F, Schmitt M, Ulm K, Gossner W and Graeff H (1989) The urokinase type of plasminogen activator (uPA) antigen is related to early relapse in breast cancer. Lancet ii: 1049
31. Jänicke F, Schmitt M, Harger R, Hollreieder A, Babic R, Ulm K, Grossner W and Graeff H (1990) Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
32. Jiang SY and Jordan VC (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84: 580-591
33. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW and Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxytamoxifen isomers in MCF-7 breast cancer cells. Cancer Res 44: 112-119
34. Kirchheimer JC, Wojta J, Christ G and Binder BR (1989) Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 86: 5424-5428
35. Kwaan HC (1992) The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev 11: 291-311
36. LaBarca C and Paigen K (1980) A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102: 344-352
37. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
38. Levenson AS, Catherino WH and Jordan VC (1997) Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 60: 261-268
39. Long BJ and Rose DP (1996) Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER. Cancer Lett 99: 209-215
40. Long BJ, Connolly JM and Rose DP (1996) Growth factor modulation of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in MDA-MB-231 and S30 human breast cancer cell lines (abstr 638). Proc Annu Meet Am Assos Cancer Res 37: 92
41. Lund LR, Rømer J, Rønne E, Ellis V, Blasi F and Danø K (1991) Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor β1 in human A549 lung carcinoma cells. EMBO J 10: 3399-3407
42. Lund LR, Rønne E, Roldan AL, Behrendt N, Rømer J, Blasi F and Danø K (1991) Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J Biol Chem 266: 5177-5181
43. Lund LR, Ellis V, Rønne E, Pyke C and Danø K (1995) Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumor promoters in the human lung carcinoma cell line A549. Biochem J 310: 345-352
44. Luperello C and Del Rosso M (1996) In vitro anti-proliferative and anti-invasive role of amino-terminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells. Eur J Cancer 32A: 702-707
45. Madsen M and Briand P (1990) Relationship between tumorigenicity, in vitro invasiveness and plasminogen activator production of human breast cancer cell lines. Eur J Cancer 26: 793-797
46. Mangel WF, Toledo DL, Nardulli AM, Reiner GCA, Norman MJ and Katzenellenbogen BS (1988) Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J Steroid Biochem 30: 79-88
47. Mizoguchi H, Uchiumi T, Ono M, Kohno K and Kuwano M (1990) Enhanced production of tissue plasminogen activator by estradiol in a novel variant of human breast cancer MCF-7 cell line. Biochim Biophys Acta 1052: 475-482
48. Needham GK, Sherbet GV, Farndon JR and Harris AL (1987) Binding of urokinase to specific receptor sites on human breast-cancer membranes. Br J Cancer 55: 13-16
49. Nielsen BS, Sehested M, Timshel S, Pyke C and Danø K (1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74: 168-177
50. Olson D, Pöllänen J, Rønne E, Høyer-Hansen G, Wun TC, Sakaguchi K, Apella E, Danø K and Blasi F (1992) Internalization of the urokinase-plasminogen activator inhibitor Type-1 complex is mediated by urokinase receptor. J Biol Chem 267: 9129-9133
51. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J and Goltzman D (1990) An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Comm 173: 1058-1064
52. Rømer J, Pyke C, Lund LR, Eriksen J, Kristensen P, Rønne E, Høyer-Hansen G, Danø K and Brünner N (1994) Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 57: 553-560
53. Ryan TJ, Seeger JI, Kumar SA and Dickerman HW (1984) Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells. J Biol Chem 259: 14324-14327
54. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L and Graeff H (1992) Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 373: 611-622
55. Shyamala V and Dickerman HW (1982) Two types of plasminogen activators secreted by MCF-7 cells. Biochem Biophys Res Comm 105: 1597-1604
56. Spyratos F, Martin PM, Hacéne K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le Doussal V, Tubiana-Hulin M and Brunet M (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272
57. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A and Baba S (1992) Plasminogen activator system in human breast cancer. Int J Cancer 50: 345-348
58. Yang NS, Park C, Lingley C and Furmanski P (1983) Effect of extracellular matrix on plasminogen activator isozyme activities of human mammary epithelial cells in culture. Mol Cell Biol 3: 982-990